Aspirin in colorectal cancer – has it still a place in secondary prevention?
Negative results from the ASCOT trial should not discourage researchers from investigating the drug’s potential in some molecularly distinct subgroups
Negative results from the ASCOT trial should not discourage researchers from investigating the drug’s potential in some molecularly distinct subgroups
Despite positive results from trials, the use of different assays with variable sensitivities and specificities impact their interpretation and clinical validation
In the NICHE-3 study, all patients achieved a pathological response
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting
Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed
Adding immunotherapy to standard of care shows benefit compared with placebo and is confirmed to be practice-changing for this patient population
Findings from the SANO trial also reported clinically complete responses after neoadjuvant chemoradiotherapy
The impact of immunotherapy on disease progression and survival remains uncertain, but biomarker selection may be the future
Recently presented results suggest that a subset of patients with early stage rectal cancer could skip pre-operative radiotherapy, thus raising some questions about the standard of care
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.